EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 173 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $406,000 | -17.8% | 7,971 | -10.0% | 0.00% | – |
| Q3 2021 | $494,000 | +37.6% | 8,861 | +5.5% | 0.00% | – |
| Q2 2021 | $359,000 | -12.4% | 8,399 | -14.4% | 0.00% | – |
| Q1 2021 | $410,000 | -8.9% | 9,814 | +1.5% | 0.00% | – |
| Q4 2020 | $450,000 | +1.6% | 9,672 | -7.3% | 0.00% | – |
| Q3 2020 | $443,000 | -13.5% | 10,433 | -2.1% | 0.00% | -100.0% |
| Q2 2020 | $512,000 | +1.8% | 10,661 | -2.4% | 0.00% | 0.0% |
| Q1 2020 | $503,000 | -19.9% | 10,927 | +4.5% | 0.00% | 0.0% |
| Q4 2019 | $628,000 | -0.2% | 10,458 | -6.0% | 0.00% | 0.0% |
| Q3 2019 | $629,000 | +15.0% | 11,127 | +13.2% | 0.00% | 0.0% |
| Q2 2019 | $547,000 | +38.8% | 9,827 | +25.8% | 0.00% | 0.0% |
| Q1 2019 | $394,000 | +53.3% | 7,811 | +22.4% | 0.00% | – |
| Q4 2018 | $257,000 | – | 6,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |